West Pharmaceutical Services’s (NYSE:WST) Q4: Beats On Revenue But Stock Drops
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 2.3% year on year to $748.8 million. On the other hand, the company’s full-year revenue guidance of $2.89 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.82 per share was 5.3% above analysts’ consensus estimates.